High-quality human clinical trials needed to determine the benefits of CBD for heart disease patientsPosted by On

As cannabidiol (CBD) use rises, high-quality randomized clinical trials are needed to determine if anti-inflammatory benefits of CBD for heart disease seen in preclinical data will work in a real-world setting, according to research presented at ACC Latin America 2022 Together with CardioAcademic. A review of existing studies found no clinical recommendations can be made given current evidence. ACC Latin America 2022 Together with CardioAcademic will be held in Mexico City on September 9-10, 2022.

“Cannabidiol and medical cannabis use, alongside its many products, has increased considerably in the last decade. Nonetheless, there are few indications for its use based on good clinical trials. Here we seek to provide preclinical evidence, which ultimately serves as the cornerstone to establishing well-designed clinical trials in humans to prove the effect of CBD on coronary syndromes with strong scientific evidence,” said Mario Esteban Zúñiga Ayala, MD, a cardiology fellow at Hospital Regional 1 o de Octubre ISSSTE in Mexico City and the study’s primary author. “CBD has substantial evidence for the following conditions: pain, cachexia, nausea and vomiting, multiple sclerosis spasticity and, most recently, epilepsy. Its pharmacological profile shows it is safe and well-tolerated in humans, although it has well-described side effects. But the interaction with other medications often used by cardiologists, such as anticoagulation and anti-platelet drugs, is not…

Original Author Link click here to read complete story..


Anti-InflammatorybloodCannabidiolcannabiscardiologydrugsheartHeart DiseasehospitalpainPreclinicalResearch

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.